BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29908284)

  • 1. Downregulation of SCARA5 may contribute to breast cancer via promoter hypermethylation.
    Ulker D; Ersoy YE; Gucin Z; Muslumanoglu M; Buyru N
    Gene; 2018 Oct; 673():102-106. PubMed ID: 29908284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of
    Wang F; Cao X; Yin L; Wang Q; He Z
    DNA Cell Biol; 2020 Oct; 39(10):1813-1824. PubMed ID: 32816580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling.
    Huang J; Zheng DL; Qin FS; Cheng N; Chen H; Wan BB; Wang YP; Xiao HS; Han ZG
    J Clin Invest; 2010 Jan; 120(1):223-41. PubMed ID: 20038795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m
    Lu X; Chen L; Liu S; Cao Y; Huang Z
    Epigenomics; 2023 Apr; 15(7):401-415. PubMed ID: 37337726
    [No Abstract]   [Full Text] [Related]  

  • 5. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile.
    Khamas A; Ishikawa T; Shimokawa K; Mogushi K; Iida S; Ishiguro M; Mizushima H; Tanaka H; Uetake H; Sugihara K
    Cancer Genomics Proteomics; 2012; 9(2):67-75. PubMed ID: 22399497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways.
    You K; Su F; Liu L; Lv X; Zhang J; Zhang Y; Liu B
    Mol Cell Biochem; 2017 Nov; 435(1-2):47-58. PubMed ID: 28497372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.
    Liu H; Hu J; Pan H; Luo D; Huang M; Xu W
    Dig Dis Sci; 2018 Jan; 63(1):155-165. PubMed ID: 29189991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis.
    Yan N; Zhang S; Yang Y; Cheng L; Li C; Dai L; Dai L; Zhang X; Fan P; Tian H; Wang R; Chen X; Su X; Li Y; Zhang J; Du T; Wei Y; Deng H
    Cancer Sci; 2012 Sep; 103(9):1631-9. PubMed ID: 22642751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
    Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
    Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rock2 promotes RCC proliferation by decreasing SCARA5 expression through β-catenin/TCF4 signaling.
    Xu Z; Hong Z; Ma M; Liu X; Chen L; Zheng C; Xi X; Shao J
    Biochem Biophys Res Commun; 2016 Nov; 480(4):586-593. PubMed ID: 27793664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
    Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent epigenetic inactivation of RSK4 by promoter methylation in cancerous and non-cancerous tissues of breast cancer.
    Li Q; Jiang Y; Wei W; Ji Y; Gao H; Liu J
    Med Oncol; 2014 Jan; 31(1):793. PubMed ID: 24338215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylated tumor suppressor gene
    Jiang X; Jiang Y; An D; Jiang X; Zhou S; Liu Y; Tian R; Li Z; Zhao X; Xiang T; Ji P; Yang Y
    Epigenomics; 2023 Jun; 15(11):635-650. PubMed ID: 37554122
    [No Abstract]   [Full Text] [Related]  

  • 19. Promoter Methylation Status Modulate the Expression of Tumor Suppressor (RbL2/p130) Gene in Breast Cancer.
    Ullah F; Khan T; Ali N; Malik FA; Kayani MA; Shah ST; Saeed M
    PLoS One; 2015; 10(8):e0134687. PubMed ID: 26271034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Expression Changes and Promoter Methylation of PLA2R1 in Tissues of Breast Cancer Patients.
    Mitwally N; Yousef E; Abd Al Aziz A; Taha M
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.